ADA and rheumatoid arthritis: We validated the B cell subset ADA-associated “module” in an independent prospective European RA cohort (n = 37) (map of recruitment is shown in Figure 3A), which was designed to assess immunogenicity development following initiation of adalimumab treatment (none of the patients included in this study had been previously treated with adalimumab) (Table 2).